CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Core Insights - CAMP4 Therapeutics Corporation has appointed Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to its Board of Directors to enhance its strategic guidance in drug development efforts [1][2] - The company focuses on developing regRNA-targeting antisense oligonucleotide (ASO) therapies aimed at upregulating gene expression to restore healthy protein levels [1][4] Company Overview - CAMP4 is a clinical-stage biotechnology company developing disease-modifying treatments for a range of genetic diseases where increasing healthy protein levels may provide therapeutic benefits [4] - The proprietary RAP Platform™ allows for targeted gene upregulation by mapping regRNAs, which are crucial in controlling gene expression [4] Leadership Expertise - Dr. Doug E. Williams has over 30 years in the biopharma industry and has contributed to the development of transformative drugs such as LEUKINE, ENBREL, and SPINRAZA [2][3] - Dr. Murray Stewart has extensive clinical development experience, having served as Chief Medical Officer at Rhythm Pharmaceuticals and held leadership roles at GlaxoSmithKline [3] Strategic Focus - The company aims to advance its lead clinical program for urea cycle disorders and preclinical program for SYNGAP1-related disorders while developing additional RNA-targeting medicines [2] - The focus is on addressing diseases where modest increases in protein levels can significantly impact patient lives [2]